Survodutide Discontinuation Rates: Phase 2 and Phase 3
Medication & Treatment UpdatesFAQ & Education

Survodutide Discontinuation Rates: Phase 2 and Phase 3

Dr Tunde Alaofin
By Dr Tunde Alaofin
Illustration of survodutide trial discontinuation rates

The specific 24.6% survodutide discontinuation figure comes from a phase 2 obesity study, where participants stopped because of treatment-emergent adverse events. SYNCHRONIZE-1 later reported its own phase 3 discontinuation rates, also around one-quarter in the active-treatment groups, alongside the 16.6% efficacy headline. Similar-looking percentages still need their own study, cause and denominator. Below, the phase 2 and phase 3 findings are kept separate.

At Maryland Trim Clinic, we discuss tolerability as part of treatment effectiveness. Our medical weight management approach considers symptoms, adequate nutrition, function, and practical burdens along with weight change.

Where does the 24.6% phase 2 figure come from?

The phase 2 study tested several survodutide doses over 46 weeks in adults without diabetes. Zealand Pharma's presentation of the phase 2 safety results, drawing on the trial report, showed adverse-event-related treatment discontinuation in 76 of 309 survodutide recipients, or 24.6%, compared with 3 of 77 placebo recipients, or 3.9%.

That percentage pooled the active dose groups. It was not the proportion of everyone in the trial who stopped for any reason. It also was not a statement that exactly one in four people receiving a future approved formulation would necessarily stop.

Gastrointestinal events were important, but the categories should remain distinct. The same presentation reported gastrointestinal-event-related discontinuation in 16.5% of survodutide recipients. The 24.6% figure concerned the broader treatment-emergent adverse-event category, so labeling all of it as gastrointestinal discontinuation would be inaccurate.

How does phase 3 change the context?

Early trials often explore doses and schedules to understand the balance of benefit and burden. Later trials may use different escalation flexibility, monitoring, or populations. A later program can address questions raised by an earlier study without making the earlier result disappear.

The SYNCHRONIZE-1 phase 3 report evaluated a different 76-week study. It supported weight reduction against placebo and documented frequent gastrointestinal adverse events. Its efficacy, safety, and discontinuation results need to be read together using their own definitions.

What were the phase 3 discontinuation rates?

In SYNCHRONIZE-1, adverse events led 57 of 241 participants (23.7%) in the 3.6-mg group and 60 of 242 (24.8%) in the 6.0-mg group to stop treatment, versus 13 of 242 (5.4%) on placebo. Gastrointestinal events accounted for 17.8%, 20.2% and 2.9%, respectively. These are treatment discontinuations, not the smaller counts of people leaving the trial because of adverse events.

A phase 2 adverse-event percentage and a phase 3 adherence-focused weight estimate cannot be presented as if they describe the same group over the same period. That shortcut can make a discussion sound precise while removing the information needed to interpret it.

The appropriate conclusion is that tolerability remains a substantive research issue. It is not that one historical percentage precisely predicts every future person's experience.

Stopping the medicine is different from leaving the trial

A participant can discontinue the study drug and remain in follow-up. This allows researchers to collect information about outcomes after treatment stops. Another participant may withdraw from follow-up entirely, creating missing data that require separate handling.

Temporary interruptions, permanent discontinuation, study withdrawal, and failure to reach a planned dose are also different events. A single word such as dropout can obscure these distinctions.

When evaluating any reported rate, identify the event, denominator, period, and reason. Ask whether the result includes all doses or one group and whether it includes all causes or only a specific adverse-event category. These questions are essential before comparing trials.

Why people may stop even while losing weight

Weight reduction does not automatically outweigh every burden. A person may experience repeated nausea, vomiting, diarrhea, constipation, or other symptoms that interfere with meals, work, sleep, or hydration. Continuing treatment can become difficult even if the scale is moving in the desired direction.

The classification mild or moderate does not tell the whole story. A symptom can remain below a trial's threshold for serious harm while being frequent enough to make daily life difficult. Patient preference is relevant to that balance.

In ordinary care, access, cost, scheduling, and competing illness can also affect continuation. A trial's adverse-event discontinuation rate does not quantify all those factors. It is one component of the broader question of whether a treatment strategy is sustainable.

Describing discontinuation as quitting can also imply a lack of commitment. A more accurate discussion asks what caused the interruption and what support or alternative was needed.

Can dropout rates rank survodutide against other medicines?

Not simply by placing adverse-event percentages from unrelated trials beside each other. Different study durations, doses, escalation rules, participant characteristics, and reporting methods can affect the apparent rates.

A direct randomized comparison using consistent definitions would provide stronger evidence for a comparative claim. Until then, cross-trial patterns can raise questions but should not be presented as a definitive ranking for individual patients.

This does not require ignoring an unfavorable signal. It means describing the signal accurately and preserving the uncertainty. A substantial discontinuation burden deserves attention even when a precise comparison with another treatment is unavailable.

For established medicines, the relevant current label and the person's history guide clinical choices. Our GLP-1 treatment information can help frame a discussion without turning separate studies into a prescribing league table.

How do discontinuations affect efficacy results?

An analysis estimating benefit with continued treatment can show what a medicine may achieve under that condition. But continued exposure is not possible for everyone. A broader treatment-regimen analysis accounts for the strategy of assigning treatment, including discontinuation.

The difference between these estimates can be clinically informative. It highlights why the ability to remain on treatment matters. It does not, by itself, tell us exactly how much difference was caused by each symptom or why every participant stopped.

For a patient, the useful question is whether a proposed plan has a realistic path to sustained benefit. That includes tolerability, monitoring, nutrition, and access, not only a target percentage of weight reduction.

What a symptom discussion should include

Illustration of phase 2 and phase 3 trial context

Describe the symptom, when it began, how often it occurs, and what it prevents you from doing. Include whether you can eat regular meals and drink normally. Mention other medicines, recent illness, and any treatment interruption.

A brief record can be useful, but serious symptoms should be reported promptly rather than saved for the next appointment. Severe persistent abdominal pain, repeated vomiting, inability to keep fluids down, or signs of dehydration need medical assessment. Severe allergic symptoms require emergency care.

If you are in an authorized clinical trial, follow the study team's instructions for reporting symptoms and treatment decisions. Do not independently alter the study regimen or add another compound to counter an effect.

Supporting nutrition without normalizing illness

Appetite reduction can make meal planning different, but it should not be equated with an obligation to eat as little as possible. Our nutrition counseling service can help address practical food concerns during established treatment.

The distinction between comfortable appetite control and illness is important. Our food noise discussion can help describe a change in food-related thoughts. Feeling less preoccupied with food is different from avoiding food because it causes distress.

If weight changes rapidly or function declines, the plan needs review. Consistent weight tracking can provide context, while strength, mobility, and symptoms add information the scale cannot supply. A plateau also deserves assessment rather than an automatic increase in treatment intensity.

What this means for someone interested in survodutide

Survodutide remains investigational. There is no routine approved prescribing plan to extract from a trial's dose groups or escalation schedule. Legitimate research participation involves eligibility, consent, monitoring, and an authorized study team.

Do not interpret a safety discussion as a set of instructions for using a research-market product. Product identity, concentration, and quality may be uncertain, and an online seller cannot reproduce a clinical trial's protections.

For current care, focus on the problem you want to solve and the established options that can be evaluated now. Bring concerns about prior symptoms or treatment interruptions to the clinician rather than assuming a newer molecule will avoid them.

Discussing a sustainable plan in Laurel

We help patients review both benefit and burden. A plan is more useful when it explains what to monitor, when to seek help, and how to reassess if treatment becomes difficult.

To discuss your options, contact Maryland Trim Clinic. The goal is care that supports health and daily function, with honest attention to the reasons someone may need a different approach.

Sources

  • Le Roux and colleagues. Phase 2 dose-finding trial of survodutide, Lancet Diabetes and Endocrinology, 2024.
  • Zealand Pharma. September 2024 presentation, phase 2 obesity safety table.
  • Le Roux and colleagues. SYNCHRONIZE-1 phase 3 trial, New England Journal of Medicine, 2026.
  • FDA. Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.

Frequently Asked Questions

Was the 24.6% phase 2 figure measured in the trial reporting 16.6% weight loss?

The commonly quoted 24.6% adverse-event discontinuation figure came from phase 2. The 16.6% headline came from a later phase 3 adherence-focused analysis. They should not be merged into one study result.

Was the entire 24.6% discontinuation rate caused by gastrointestinal events?

No. It concerned all treatment-emergent adverse events leading to discontinuation. Gastrointestinal-event-related discontinuation was a separate, smaller category in that phase 2 table.

Does stopping a medicine mean treatment has failed?

Not necessarily. Symptoms, safety, access, and patient priorities can justify a change. The reason for stopping should guide the next decision.

Should someone tolerate persistent vomiting to obtain a better weight result?

No. Persistent vomiting or difficulty maintaining hydration needs medical assessment. A weight target is not a reason to ignore a potentially serious problem.


Talk Through Treatment Tolerability

Review your options with a clinician who can discuss benefit, side effects, and what to watch for next.

Schedule Consultation Now